Abstracts tagged "Adalimumab and juvenile idiopathic arthritis (JIA)"

Abstract Number: 385 • 2016 ACR/ARHP Annual Meeting
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Kliniken GmbH, Hamburg, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 2452 • 2015 ACR/ARHP Annual Meeting
Clinical and Functional Outcomes in Patients with Polyarticular Juvenile Idiopathic Arthritis Following Treatment with Adalimumab
Daniel J. Kingsbury¹, Pierre Quartier², G Horneff³, Kirsten Minden⁴, Mary Toth⁵, Nupun A. Varothai⁶, Anabela Cardoso⁷ and Jasmina Kalabic⁶, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Hopital Necker-Enfants Malades, Paris, France, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁵Akron Children's Hospital, Akron, OH, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Amadora, Portugal
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) is increasingly accepted for defining a treat-to-target strategy in patients (pts) with juvenile idiopathic arthritis (JIA)1 The…
Abstract Number: 2428 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Adult Patients with Polyarticular Juvenille Idiopathic Arthritis
Daniel Lovell^1,2, Nicolino Ruperto³, Andreas Reiff⁴, Lawrence Jung⁵, Katerina Jarosova⁶, Pierre Quartier⁷, Christy Sandborg⁸, John F. Bohnsack⁹, Dirk Elewaut¹⁰, Ivan Foeldvari¹¹, Joseph Rovensky¹², Edward H. Giannini², Nupun A. Varothai¹³, Jasmina Kalabic¹³ and Alberto Martini^14,15,16, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁴Children's Hospital, Los Angeles, CA, ⁵Pediatric Rheumatology, Children's National Med Ctr, Washington, DC, ⁶Revmatologicky ustav, Prague, Czech Republic, ⁷Hospital Necker Enfants Malades, Paris, France, ⁸Stanford University Medical Center, Standford, CA, ⁹Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, ¹⁰Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, ¹¹Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹²The National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹³AbbVie, North Chicago, IL, ¹⁴University of Genova, Genova, Italy, ¹⁵Department of Pediatrics, University of Genova, Genova, Italy, ¹⁶Istituto Gaslini-PRINTO, Genova, Italy
Background/Purpose: The diagnosis of polyarticular JIA (pJIA) is made in childhood but the disease and the diagnosis are carried into adulthood. Adults with pJIA have…
Abstract Number: 279 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Vipin Arora³, Jasmina Kalabic⁴, Hartmut Kupper⁴ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ³AbbVie, North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US,…